256 related articles for article (PubMed ID: 19740332)
41. Human papillomavirus (HPV) type 16 E7 protein bodies cause tumour regression in mice.
Whitehead M; Ohlschläger P; Almajhdi FN; Alloza L; Marzábal P; Meyers AE; Hitzeroth II; Rybicki EP
BMC Cancer; 2014 May; 14():367. PubMed ID: 24885328
[TBL] [Abstract][Full Text] [Related]
42. DNA Vaccine Encoding HPV16 Oncogenes E6 and E7 Induces Potent Cell-mediated and Humoral Immunity Which Protects in Tumor Challenge and Drives E7-expressing Skin Graft Rejection.
Chandra J; Dutton JL; Li B; Woo WP; Xu Y; Tolley LK; Yong M; Wells JW; R Leggatt G; Finlayson N; Frazer IH
J Immunother; 2017; 40(2):62-70. PubMed ID: 28166181
[TBL] [Abstract][Full Text] [Related]
43. Prophylactic and therapeutic efficacy of an attenuated Listeria monocytogenes-based vaccine delivering HPV16 E7 in a mouse model.
Jia Y; Yin Y; Duan F; Fu H; Hu M; Gao Y; Pan Z; Jiao X
Int J Mol Med; 2012 Dec; 30(6):1335-42. PubMed ID: 23027427
[TBL] [Abstract][Full Text] [Related]
44. Different domains of glycoprotein 96 influence HPV16 E7 DNA vaccine potency via electroporation mediated delivery in tumor mice model.
Daemi A; Bolhassani A; Rafati S; Zahedifard F; Hosseinzadeh S; Doustdari F
Immunol Lett; 2012 Dec; 148(2):117-25. PubMed ID: 23085605
[TBL] [Abstract][Full Text] [Related]
45. Induction of robust cellular immunity against HPV6 and HPV11 in mice by DNA vaccine encoding for E6/E7 antigen.
Shin TH; Pankhong P; Yan J; Khan AS; Sardesai NY; Weiner DB
Hum Vaccin Immunother; 2012 Apr; 8(4):470-8. PubMed ID: 22336879
[TBL] [Abstract][Full Text] [Related]
46. The contribution of NT-gp96 as an adjuvant for increasing HPV16 E7-specific immunity in C57BL /6 mouse model.
Mohit E; Bolhassani A; Zahedifard F; Taslimi Y; Rafati S
Scand J Immunol; 2012 Jan; 75(1):27-37. PubMed ID: 21916914
[TBL] [Abstract][Full Text] [Related]
47. A synthetic chimeric peptide harboring human papillomavirus 16 cytotoxic T lymphocyte epitopes shows therapeutic potential in a murine model of cervical cancer.
Sharma C; Khan MA; Mohan T; Shrinet J; Latha N; Singh N
Immunol Res; 2014 Jan; 58(1):132-8. PubMed ID: 24174302
[TBL] [Abstract][Full Text] [Related]
48. Comparison of six cell penetrating peptides with different properties for in vitro and in vivo delivery of HPV16 E7 antigen in therapeutic vaccines.
Shahbazi S; Bolhassani A
Int Immunopharmacol; 2018 Sep; 62():170-180. PubMed ID: 30015237
[TBL] [Abstract][Full Text] [Related]
49. Optimization of human papillomavirus (HPV) type 16 E7-expressing lactobacillus-based vaccine for induction of mucosal E7-specific IFNγ-producing cells.
Komatsu A; Igimi S; Kawana K
Vaccine; 2018 Jun; 36(24):3423-3426. PubMed ID: 29735324
[TBL] [Abstract][Full Text] [Related]
50. Induction of CD4-independent E7-specific CD8+ memory response by heat shock fusion protein.
Liu H; Wu BH; Rowse GJ; Emtage PC
Clin Vaccine Immunol; 2007 Aug; 14(8):1013-23. PubMed ID: 17596433
[TBL] [Abstract][Full Text] [Related]
51. Intranasal immunization with synthetic peptides corresponding to the E6 and E7 oncoproteins of human papillomavirus type 16 induces systemic and mucosal cellular immune responses and tumor protection.
Manuri PR; Nehete B; Nehete PN; Reisenauer R; Wardell S; Courtney AN; Gambhira R; Lomada D; Chopra AK; Sastry KJ
Vaccine; 2007 Apr; 25(17):3302-10. PubMed ID: 17291642
[TBL] [Abstract][Full Text] [Related]
52. Genetically modified cellular vaccines for therapy of human papilloma virus type 16 (HPV 16)-associated tumours.
Bubenik J
Curr Cancer Drug Targets; 2008 May; 8(3):180-6. PubMed ID: 18473731
[TBL] [Abstract][Full Text] [Related]
53. Evaluation of immune responses induced by a novel human papillomavirus type 16 E7 peptide-based vaccine with Candida skin test reagent as an adjuvant in C57BL/6 mice.
Wang X; Che Y; Chen B; Zhang Y; Nakagawa M; Wang X
Int Immunopharmacol; 2018 Mar; 56():249-260. PubMed ID: 29414659
[TBL] [Abstract][Full Text] [Related]
54. A Chlamydomonas-derived Human Papillomavirus 16 E7 vaccine induces specific tumor protection.
Demurtas OC; Massa S; Ferrante P; Venuti A; Franconi R; Giuliano G
PLoS One; 2013; 8(4):e61473. PubMed ID: 23626690
[TBL] [Abstract][Full Text] [Related]
55. Combined prophylactic and therapeutic intranasal vaccination against human papillomavirus type-16 using different adeno-associated virus serotype vectors.
Nieto K; Kern A; Leuchs B; Gissmann L; Müller M; Kleinschmidt JA
Antivir Ther; 2009; 14(8):1125-37. PubMed ID: 20032542
[TBL] [Abstract][Full Text] [Related]
56. Administration of HPV DNA vaccine via electroporation elicits the strongest CD8+ T cell immune responses compared to intramuscular injection and intradermal gene gun delivery.
Best SR; Peng S; Juang CM; Hung CF; Hannaman D; Saunders JR; Wu TC; Pai SI
Vaccine; 2009 Sep; 27(40):5450-9. PubMed ID: 19622402
[TBL] [Abstract][Full Text] [Related]
57. DNA vaccine encoding endosome-targeted human papillomavirus type 16 E7 protein generates CD4+ T cell-dependent protection.
Brulet JM; Maudoux F; Thomas S; Thielemans K; Burny A; Leo O; Bex F; Hallez S
Eur J Immunol; 2007 Feb; 37(2):376-84. PubMed ID: 17274002
[TBL] [Abstract][Full Text] [Related]
58. Induction of antitumor immunity in vivo following delivery of a novel HPV-16 DNA vaccine encoding an E6/E7 fusion antigen.
Yan J; Reichenbach DK; Corbitt N; Hokey DA; Ramanathan MP; McKinney KA; Weiner DB; Sewell D
Vaccine; 2009 Jan; 27(3):431-40. PubMed ID: 19022315
[TBL] [Abstract][Full Text] [Related]
59. A vaccine conjugate of 'ISCAR' immunocarrier and peptide epitopes of the E7 cervical cancer-associated protein of human papillomavirus type 16 elicits specific Th1- and Th2-type responses in immunized mice in the absence of oil-based adjuvants.
Tindle RW; Croft S; Herd K; Malcolm K; Geczy AF; Stewart T; Fernando GJ
Clin Exp Immunol; 1995 Aug; 101(2):265-71. PubMed ID: 7544248
[TBL] [Abstract][Full Text] [Related]
60. Bivalent therapeutic vaccine against HPV16/18 genotypes consisting of a fusion protein between the extra domain A from human fibronectin and HPV16/18 E7 viral antigens.
Arribillaga L; Echeverria I; Belsue V; Gomez T; Lozano T; Casares N; Villanueva L; Domingos-Pereira S; Romero PJ; Nardelli-Haefliger D; Hervás-Stubbs S; Sarobe P; Rodriguez MJ; Carrascosa JL; Zürcher T; Lasarte JJ
J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32581060
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
